Welcome to LookChem.com Sign In|Join Free
  • or
2-(2,3,4,6-tetrafluorophenyl)acetonitrile is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

53001-75-5

Post Buying Request

53001-75-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

53001-75-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 53001-75-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,0,0 and 1 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 53001-75:
(7*5)+(6*3)+(5*0)+(4*0)+(3*1)+(2*7)+(1*5)=75
75 % 10 = 5
So 53001-75-5 is a valid CAS Registry Number.

53001-75-5Relevant academic research and scientific papers

Unprecedented Reversal of Regioselectivity during Methanolysis and an Interception of Curtius Rearrangement

Brunskill, Andrew,Buevich, Alexei V.,Caldwell, John P.,Cumming, Jared,Liu, Xiaoxiang,Mandal, Mihirbaran,Mazzola, Robert,McKittrick, Brian,Orth, Peter,Stamford, Andrew,Wang, Hongwu,Zhu, Zhaoning

supporting information, p. 5073 - 5079 (2021/09/28)

Unprecedented reversal in regioselectivity during methanolysis of anhydrides due to the change in substitution pattern of fluorine in the phenyl moiety, and the formation of nitrene intercepted intermediates during Curtius rearrangement of the acids were the major impediments for discovering bioactive molecules in beta amyloid cleaving enzyme-1 (BACE1) program. Solutions to these synthetic challenges, and our investigation into this unexpected change in reactivity are discussed.

Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates

Mandal, Mihirbaran,Wu, Yusheng,Misiaszek, Jeffrey,Li, Guoqing,Buevich, Alexei,Caldwell, John P.,Liu, Xiaoxiang,Mazzola, Robert D.,Orth, Peter,Strickland, Corey,Voigt, Johannes,Wang, Hongwu,Zhu, Zhaoning,Chen, Xia,Grzelak, Michael,Hyde, Lynn A.,Kuvelkar, Reshma,Leach, Prescott T.,Terracina, Giuseppe,Zhang, Lili,Zhang, Qi,Michener, Maria S.,Smith, Brad,Cox, Kathleen,Grotz, Diane,Favreau, Leonard,Mitra, Kaushik,Kazakevich, Irina,McKittrick, Brian A.,Greenlee, William,Kennedy, Matthew E.,Parker, Eric M.,Cumming, Jared N.,Stamford, Andrew W.

, p. 3231 - 3248 (2016/05/19)

We describe successful efforts to optimize the in vivo profile and address off-target liabilities of a series of BACE1 inhibitors represented by 6 that embodies the recently validated fused pyrrolidine iminopyrimidinone scaffold. Employing structure-based design, truncation of the cyanophenyl group of 6 that binds in the S3 pocket of BACE1 followed by modification of the thienyl group in S1 was pursued. Optimization of the pyrimidine substituent that binds in the S2′-S2″ pocket of BACE1 remediated time-dependent CYP3A4 inhibition of earlier analogues in this series and imparted high BACE1 affinity. These efforts resulted in the discovery of difluorophenyl analogue 9 (MBi-4), which robustly lowered CSF and cortex Aβ40 in both rats and cynomolgus monkeys following a single oral dose. Compound 9 represents a unique molecular shape among BACE inhibitors reported to potently lower central Aβ in nonrodent preclinical species.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 53001-75-5